Previous close | 396.20 |
Open | 396.20 |
Bid | 374.62 x 100 |
Ask | 393.06 x 100 |
Day's range | 391.70 - 396.69 |
52-week range | 320.01 - 448.40 |
Volume | |
Avg. volume | 1,131,222 |
Market cap | 101.525B |
Beta (5Y monthly) | 0.37 |
PE ratio (TTM) | 28.26 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Vertex's (VRTX) revenues in the first quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.